Cyclin C – a novel therapeutic target for treating B-ALL
28. October 2024 2024-10-28 14:51Cyclin C – a novel therapeutic target for treating B-ALL

Cyclin C – a novel therapeutic target for treating B-ALL
Despite significant therapeutic advancements in the treatment of acute lymphoblastic leukemia (ALL), challenges like drug resistance and long-term toxicities continue to hinder effective treatment. In a study led by Dagmar Gotthardt and Veronika Sexl, with support from the SFB and the Tissue Home program and esteemed international collaborators, first author Jana Trifinopoulos has identified cyclin C as a crucial factor in the development and maintenance of B-ALL. Importantly, while cyclin C is non-essential for normal hematopoiesis, its role in B-ALL suggests that targeting cyclin C could be a promising therapeutic strategy to increase cancer cell sensitivity to stress and chemotherapy.
Published in Haematologica
Jana Trifinopoulos, Julia List, Thorsten Klampfl, Klara Klein, Michaela Prchal-Murphy, Agnieszka Witalisz-Siepracka, Florian Bellutti, Luca L. Fava, Gerwin Heller, Sarah Stummer, Patricia Testori, Monique L. den Boer, Judith M. Boer, Sonja Marinovic, Gregor Hoermann, Wencke Walter, Andreas Villunger, Piotr Sicinski, Veronika Sexl, Dagmar Gotthardt
Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress response

Related Posts
A tailored mouse model for unravelling the development of NK cell malignancy
Finally – Joint Effort of all SFB Members Published
Targeting STAT5 in hematopoietic cancers
Change of Subproject Leadership
Search
Categories